Omeros Corporation (NASDAQ:OMER - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $20.43 and last traded at $20.4180, with a volume of 498257 shares changing hands. The stock had previously closed at $18.49.
Analyst Ratings Changes
Several equities research analysts have recently commented on OMER shares. Zacks Research cut shares of Omeros from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. Cantor Fitzgerald upgraded shares of Omeros from a "neutral" rating to an "overweight" rating and set a $22.00 target price on the stock in a report on Tuesday, September 22nd. Weiss Ratings lowered shares of Omeros from a "hold (c)" rating to a "hold (c-)" rating in a research note on Tuesday, September 22nd. HC Wainwright reissued a "buy" rating on shares of Omeros in a research note on Monday, July 27th. Finally, Wall Street Zen raised shares of Omeros from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $34.00.
Get Our Latest Analysis on Omeros
Omeros Stock Down 0.2%
The firm's fifty day simple moving average is $16.40 and its 200-day simple moving average is $13.11. The firm has a market capitalization of $1.40 billion, a PE ratio of 15.15 and a beta of 2.60.
Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to analysts' expectations of $12.69 million. As a group, analysts predict that Omeros Corporation will post -0.37 earnings per share for the current year.
Insider Transactions at Omeros
In other Omeros news, Director Thomas Cable sold 15,000 shares of the stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $18.45, for a total value of $276,750.00. Following the transaction, the director owned 35,067 shares of the company's stock, valued at approximately $646,986.15. This represents a 29.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Peter Cancelmo sold 25,000 shares of the business's stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $18.54, for a total value of $463,500.00. Following the sale, the vice president owned 200 shares of the company's stock, valued at approximately $3,708. This represents a 99.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 105,906 shares of company stock worth $1,989,705. 10.50% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Omeros
Several institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp raised its stake in shares of Omeros by 20.9% in the second quarter. State Street Corp now owns 2,319,906 shares of the biopharmaceutical company's stock worth $22,062,000 after buying an additional 400,331 shares during the period. Engineers Gate Manager LP purchased a new stake in shares of Omeros in the second quarter worth $138,000. Squarepoint Ops LLC bought a new stake in Omeros during the second quarter valued at about $523,000. Arizona State Retirement System bought a new stake in Omeros during the 2nd quarter valued at approximately $179,000. Finally, HighTower Advisors LLC lifted its holdings in shares of Omeros by 4.3% in the second quarter. HighTower Advisors LLC now owns 115,368 shares of the biopharmaceutical company's stock worth $1,097,000 after buying an additional 4,738 shares in the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.
About Omeros
(
Get Free Report)
Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.
Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.
See Also
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
